Sign in Register

Methylergonovine Maleate (methylergonovine maleate)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Ergonovine maleate and methylergonovine maleate, which are amine ergot alkaloids, directly stimulate contractions of uterine smooth muscle.

Ergonovine maleate and methylergonovine maleate are used for the prevention and treatment of postpartum hemorrhage caused by uterine atony. The drugs appear to be equally effective for these purposes; however, many clinicians prefer methylergonovine to ergonovine because the former drug may produce hypertension less frequently than does the latter drug. Methylergonovine is a first-line agent for the treatment of postpartum hemorrhage; methylergonovine usually is given after oxytocin.

Administration of parenteral ergot alkaloids during the third stage of labor decreases mean blood loss and the incidence of postpartum blood loss of 500 mL or more. Ergonovine and methylergonovine should not be used for the induction or augmentation of labor.

Generic name: methylergonovine maleate
Pronunciation: (METH-ill-er-go-NO-veen)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Methylergonovine Maleate

Intelligence content is not available yet.

Indications

The following indications are listed for Methylergonovine Maleate:

  • Postpartum Hemorrhage
  • Prevention Of Uterine Inertia

Also known as: Postpartum Bleeding, Prevention Of Uterine Atony.

Dosing

For the prevention and treatment of postpartum hemorrhage, the IM dose of ergonovine maleate is 0.2 mg; the dose can be repeated as necessary. The manufacturer states that it is rarely necessary to administer IM doses more frequently than every 2-4 hours. Following IM administration, the drug can be given orally to minimize late postpartum bleeding. The usual oral dosage of ergonovine maleate to minimize late postpartum bleeding is 0.2-0.4 mg every 6-12 hours until uterine atony has passed (usually 48 hours). Severe uterine cramping may be reduced by decreasing dosage. Ergonovine maleate tablets also may be administered sublingually.

For the prevention and treatment of postpartum hemorrhage, the IM dose of methylergonovine maleate is 0.2 mg; the dose can be repeated as necessary every 2-4 hours. For excessive uterine bleeding or other emergency situations, the same dose may be given IV, but blood pressure and uterine contractions should be carefully monitored. To control uterine bleeding during the puerperium, methylergonovine maleate can be administered orally in a dosage of 0.2 mg 3 or 4 times daily for a maximum of 1 week postpartum.

When used as a provocative test+ in the diagnosis of variant angina, ergonovine maleate has been administered IV in a dose of 0.1-0.4 mg.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data